EVOLUTION AT MERCK - INVENTING FOR LIFE
KEYTRUDA: SIGNIFICANT GLOBAL GROWTH
OPPORTUNITIES
•
Building on leadership in lung with
additional reimbursement rolling out across
Europe and other markets
$10,000
KEYTRUDA is one of the best-selling
drugs 6 years after launch
$9,000
•
Encouraged by early adoption in RCC and
adjuvant melanoma launches
$8,000
$7,000
•
Excited to extend H&N leadership with
recent 1L approval
$6,000
Indications expected to more than double
over next 5 years
O Earlier lines of therapy, including
adjuvant / neoadjuvant
。 New combinations
。 New tumor types
$5,000
$4,000
$3,000
$2,000
$1,000
KEYTRUDA
(pembrolizumab) 100
LIPITOR
atorvastatin calcium
OPDIVO.
(nivolumab
sabers
$0
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Source: Evaluate Pharma; KEYTRUDA Year 6 sales represent 1Q 2019 sales annualized. Sales in $ billions and not inflation adjusted
MERCK
INVENTING FOR LIFE
#
Frank Clyburn
20View entire presentation